Dr Cornelius mentioned that the OBP's product portfolio constitutes bacterial vaccine products, viral vaccine products and other products such as frozen infective blood that is manufactured in conjunction with the ARC- OVI and antiserum diagnostic reagents such as dourine and rose Bengal. The following threats and constraints were reported by the CEO: . Negative perception of the OBP brand (RVF); . Products not available due to equipment breakdown and old outdated production processes, which causes unreliable supply; . No innovation meaning that OBP cannot afford new technology to develop new products; . Budget constraints - limited market and growth potential; . OBP is a commercial entity but also carries within its portfolio, products that are earmarked for public good and product availability to fulfil orders is a major constraint mainly due to technology and equipment constraints; . Factors affecting production and sales (market share and sales revenue), which are also factors affecting the activities within the company; and . Non-GMP (Good Manufacturing Practice) status - currently operation under ISO (International Standards of Operation).